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and have a poor outcome.
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(Affiliations continued on next page)SUMMARYThe HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in
addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma
(HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated
with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors
(mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleo-
morphic xanthoastrocytoma ([PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more
CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups
(hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials
will need to take into account the diversity represented by the term ‘‘HGG’’ in the pediatric population.INTRODUCTION
High-grade gliomas (HGGs) in children, like their adult counter-
parts, continue to have a bleak prognosis, with a median overall
survival (OS) of 9–15 months (Cohen et al., 2011; Jones et al.,Significance
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(Jones and Baker, 2014; Mackay et al., 2017; Paugh et al., 2010;
Schwartzentruber et al., 2012; Sturm et al., 2012;Wu et al., 2012,
2014). Histone wild-type (WT) tumors have widely differing muta-
tional burdens, ranging from infant cases (<3 years) driven by
single gene fusion events through to patients with biallelic
mismatch repair deficiency harboring some of the highest muta-
tional rates in human cancer (Jones and Baker, 2014; Mackay
et al., 2017; Shlien et al., 2015; Wu et al., 2014).
The rapid advances in our understanding of pHGGs have come
predominantly from the accumulation of numerous disparate
retrospective collections, a reflection of the rarity of the disease.
Clinical trial cohorts with ancillary biomarker analyses have
been relatively limited in their scope, and historically have focused
on single-marker analyses. These include the Children’s
Oncology Group ACNS0126 (radiotherapy [RT]/temozolomide
[TMZ]) (Cohen et al., 2011) and ACNS0423 (RT/TMZ followed
by TMZ and lomustine) (Jakacki et al., 2016) studies, which report
on the frequency and clinical correlations of O6-methylguanine-
DNAmethyltransferase (MGMT) expression (ACNS0126) (Jakacki
et al., 2016; Pollack et al., 2006), IDH1 mutation (ACNS0423)
(Pollack et al., 2011), as well as phosphorylated Akt expression
(Pollack et al., 2010a) and microsatellite instability (both)
(Pollack et al., 2010b). The CCG-945 study (‘‘8 in 1’’ chemo-
therapy) (Finlay et al., 1995) reported on the prognostic
significance of p53 expression/mutation (Pollack et al., 2002), in
addition to the presence/absence of 1p19q co-deletion (Pollack
et al., 2003b).
This last study (Pollack et al., 2003b) also highlighted the crit-
ical importance of pathological review in the diagnosis of pHGG,
and subsequent interpretation of clinical trial results (Gilles et al.,
2008; Pollack et al., 2003a), particularly in midline locations
(Eisenstat et al., 2015). It has subsequently become clear that
numerous histological subtypes of HGG can harbor distinct
genetic drivers and have considerably better clinical outcomes,
such as BRAF_V600E mutations in epithelioid glioblastoma830 Cancer Cell 33, 829–842, May 14, 2018(GBM), anaplastic ganglioglioma, and anaplastic pleomorphic
xanthoastrocytoma (PXA) (Hatae et al., 2016); in the latter two
categories, this mutation is also found in lower-grade entities
lacking obvious anaplasia. Additional histoneWT cases of other-
wise uncontroversial HGGs have been found to be biologically
and clinically more similar to several types of low-grade
glioma (LGG) and PXA (Korshunov et al., 2015), highlighting the
importance of an integrated diagnosis combining molecular
and histological features.
The HERBY trial (study BO25041; clinicaltrials.gov
NCT01390948) was a phase II, open-label, randomized, multi-
center, comparator study of the addition of the anti-angiogenic
agent bevacizumab (BEV) to RT and TMZ in patients between
the ages of 3 and 18 years with newly diagnosed non-brainstem
HGG (Grill et al., 2018). Central confirmation of HGG diagnosis
was mandatory before randomization, followed by consensus
review by five independent expert neuropathologists. Real-
time panel radiological assessment was also incorporated. An
exploratory endpoint of the study was to establish a bio-
specimen repository for correlative molecular profiling. In addi-
tion to its role in tumor angiogenesis, vascular endothelial
growth factor (VEGF) restricts immune cell activity, and BEV
has been demonstrated to facilitate recruitment of T cells to infil-
trate tumors (Wallin et al., 2016), as well as increase the ratio of
CD8+CD3+ T cells in adult GBM specimens (Scholz et al., 2016).
We therefore also sought to explore the immune profile of cases
within the HERBY cohort.
RESULTS
The Translational Research Cohort Is Representative of
the Whole Clinical Trial Population
The total HERBY cohort comprised 121 randomized patients at
diagnosis (3–18 years) plus 3 infant cases (<3 years) at relapse.
Of these, 113 patients consented to the translational research
program (Table S1). Tumor tissue was collected from either
Figure 1. Sample Cohort
(A) Flow diagram indicating total HERBY trial cohort (n = 121 randomized plus 3 infants), those patients consenting to the biology study (n = 113) for whom
sufficient formalin-fixed paraffin-embedded (FFPE) or frozen tumor was available (n = 89), and the respective molecular analyses undertaken.
(B–D) Kaplan-Meier plots of event-free survival of cases (y axis) separated by treatment arm (B), anatomical location (C), or H3F3A status (D), with time given in
months (x axis) and the overall p value provided, calculated by the log rank test. Individual pairwise comparisons are provided in the text.
See also Table S1.resection (n = 93) or biopsy (n = 20), although 24 cases failed to
provide sufficient quantity or quality of sample for molecular anal-
ysis. For the remaining 89 cases, material was available in the
form of either fresh-frozen material (n = 36), formalin-fixed
paraffin-embedded pathology specimens (n = 79), or both (n =
26). These were subjected to Sanger sequencing for H3F3A
(n = 89), exome sequencing (n = 86), Illumina 450k methylation
BeadChip profiling (n = 74), CD8 immunohistochemistry (n =
70), methylation-specific PCR for MGMT promoter methylation
(n = 36), a capture-based sequencing panel for common fusion
gene detection (n = 68), and RNA sequencing (RNA-seq) (n =
20) (Figure 1A).The translational research cohort, representing a subset (91%)
of the randomized trial, displayed equivalent clinical characteris-
tics to the full dataset (Grill et al., 2018), with no difference in the
primary endpoint of 1-year event-free survival (EFS) with the
addition of BEV to the standard therapy of TMZ and RT (median
12.0 versus 8.3 months, p = 0.372, log rank test), with an addi-
tional small (n = 3) infant cohort treated with BEV at relapse (Fig-
ure 1B). The cohort contained 66 (58%) hemispheric and 47
(42%) non-brainstem midline tumors, with the latter location
conferring a significantly shorter EFS (median 8.0 versus
14.7 months, p = 0.00201, log rank test) (Figure 1C). Histone
mutation status was a significant predictor of worse prognosisCancer Cell 33, 829–842, May 14, 2018 831
compared with WT (median EFS = 11.3 months) for
H3F3A_K27M (24/89, 27%; median EFS = 7.9 months;
p = 0.0063, log rank test) and also trended toward shorter
survival forH3F3A_G34R/V (7/89, 8%;medianEFS=8.3months;
p = 0.096, log rank test) (Figure 1D).
Integrated Molecular Analysis Defines the Major (Epi)
genomic Alterations in pHGG
We used the Heidelberg brain tumor classifier on Illumina 450k
methylation array data to assign a molecular subgroup to each
of 74 samples for which such data were available (Table S2).
After excluding low-scoring assignments (<0.2), we used a
simplified system to classify tumors as either H3K27M (n = 18),
H3G34R/V (n = 6), or IDH1 (n = 4) (integrating gene mutation
data in low-scoring cases); as resembling PXA-like (n = 9) or
other LGG-like (n = 3); and aggregating the remaining tumors
(HGG-WT, n = 34) (Figure 2A). IDH1 tumors represented the old-
est patients (median = 17.2 years, others = 11.2, p = 0.0107,
t test), with LGG-like representing the youngest category
(median = 5.7 years, p = 0.0098, t test) (Figure 2B). These two
subgroups each had significantly better outcome in terms of
EFS (p = 0.0281 and p = 0.0386, log rank test), although not
OS (p = 0.0935 and p = 0.129, log rank test) (Figure 2C), when
compared individually to the remaining tumors. The PXA-like
showed a trend toward longer OS (p = 0.0867, log rank test)
compared with the rest. When IDH1, PXA-like, and LGG-like
tumors were excluded from the analysis, the significant differ-
ences between histone mutant and HGG-WT groups were ab-
sent (H3K27M, p = 0.257 EFS and p = 0.0746 OS; H3G34R/V,
p = 0.552 EFS and p = 0.116 OS, log rank test). Twelve out of
78 (15%) samples harbored a methylated MGMT promoter,
although this was largely restricted to the H3G34R/V (n = 3,
p = 0.0249, Fishers exact test) and IDH1 (n = 3, p = 0.0062,
Fisher’s exact test) subgroups (Figure S1A), and was not signif-
icantly associated with survival (Figure S1B) in these uniformly
TMZ-treated patients.
We used a 450k methylation array and exome-sequencing
coverage to derive DNA copy-number profiles for 86 pHGG
(Figure S2A), including focal amplifications/deletions, as well
as whole-arm chromosomal gains/losses (Table S3). Taken
with the somatic single-nucleotide variants (SNVs) and small
insertion/deletions from whole-exome sequencing (Table S3),
and candidate gene fusion events from capture-based panel
sequencing (n = 68) and RNA-seq (n = 20) (Table S3), we
derived an integrated map of genetic alterations across the
translational research cohort (Figure 3A). The most common
alteration was TP53 mutation (39/82, 48%), followed by
ATRX deletion/mutation (25/82, 30%), PDGFRA amplification/
mutation (17/82, 21%), and CDKN2A/B deletion (15/82,
18%). Additional recurrent alterations in receptor tyrosine
kinases (EGFR, MET, ERBB3, IGF1R, and NTRK2), phosphati-
dylinositol 3-kinase (PI3K)/mammalian target of rapamycin
(PTEN, PIK3CA, TSC2, and PIK3R1), and MAP-kinase (NF1,
BRAF, PTPN11, and PTPN12) pathways were common, as
were amplifications/mutations in various genes associated
with cell-cycle regulation (RB1, CDK4, MDM2, and CCND2).
Taking a minimum variant allele frequency of 5% as a
threshold, the median number of somatic mutations per sam-
ple was 15 (range = 0–337) (Figure 3B), with the exception of832 Cancer Cell 33, 829–842, May 14, 2018four cases for whom there were more than 100-fold more,
and were excluded from gene-level counts.
pHGGs Comprise a Diverse Set of Biological and
Clinicopathological Subgroups
Two cases were highlighted from the methylation subgrouping
as potentially representing non-HGG entities. One case classi-
fying as CNS neuroblastoma with FOXR2 activation (CNS NB-
FOXR2, methylation classifier score = 0.617), was found to
have no evidence of FOXR2 alterations. A further case, a
compact and necrotic tumor with perivascular radiating arrange-
ments (Figure S2B), displayed a methylation classifier score
strongly indicative of a high-grade neuroepithelial tumor with
MN1 alteration (CNS HGNET-MN1, methylation classifier
score = 0.713) (Figure S2C). We identified a candidate alteration
in this case fusing exon 1 ofMN1 (22q12.1) to exon 3 of CARD6
(5p13.1) (Figure S2D), and thus appearsmost likely to fall into this
categorization.
Three cases classified more closely to either pilocytic astro-
cytoma (n = 2) or desmoplastic infantile ganglioglioma (DIG)
(n = 1) by 450k methylation profiling. The first two harbored
mitogen-activated protein kinase (MAPK) dysregulation in the
form of either BRAF_V600E or intragenic FGFR1 duplication
(Figure S2E). Histologically, after Pathology Committee re-
review, no piloid features were seen, and anaplastic features
were evident (Figure S2F). The DIG-like case was found in the
infant cohort (2.7 years). None of these three patients died dur-
ing the course of follow-up, and, although numbers are small,
were all found in the right frontal and temporo-parietal lobes
with central predominance (Figure S2G).
There were four cases with IDH1 hotspot mutations (Fig-
ure S3A). Three were classified as WHO-grade III anaplastic as-
trocytoma (AA), IDH1_R132-positive by immunohistochemistry,
with concurrent TP53 and ATRX mutations. The remaining
case was originally classified as a mixed oligo-astrocytoma,
which, by virtue of the presence of IDH1_R132 and TERT pro-
motermutation (C228T), aswell as copy-number loss of chromo-
somes 1p and 19q, would be described as an oligodendroglioma
according to WHO 2016 (Figure S3B). Across the whole cohort,
IDH1 mutation conferred a significantly longer EFS (p = 0.0398,
log rank test), although not OS (p = 0.110, log rank test) (Fig-
ure S3C), and were restricted to the frontal lobes (Figure S3D).
After excluding IDH1mutant cases, the remaining H3F3A and
BRAF WT cases (n = 38) represented a heterogeneous mix of
genomic profiles, with recurrent deletions/mutations in the com-
mon pHGG tumor suppressor genes TP53 (n = 11), ATRX (n = 5),
CDKN2A/B (n = 7),NF1 (n = 8), RB1 (n = 7), and PTEN (n = 5), but
also with an enrichment of gene amplifications in PDGFRA
(n = 5, with KIT and KDR, n = 4), CDK4 (n = 7, with MDM2,
n = 4), EGFR (n = 4), MET (n = 2), CCND2 (n = 3), and MYCN
(n = 3) (Figure S3E). The most common methylation subclass
in these cases was designated GBM_RTK_MYCN (n = 6); how-
ever, it included only one of those withMYCN amplification, and
with no other common amplifications or mutations. Seven cases
harbored none of the recurrently altered genes previously
described in pHGG, and clearly represent a subgroup that war-
rants further investigation. Together, these cases had bilateral
hemispheric distribution with predominant deep right cerebral
localization (Figure S3F).
Figure 2. Methylation-Based Subclassification
(A) Heatmap representation of b values for 74 samples profiled on the Illumina 450k BeadChip platform (red, high; blue, low). Samples are arranged in columns
clustered by probes with the largest median absolute deviation across the 10k predictor subset of probes. Clinicopathological and molecular annotations are
provided as bars according to the included key. CR/PR, complete response or partial response; Stable/NC, stable disease or no change.
(B) Boxplot showing age at diagnosis of included cases, separated bymethylation subclass. The thick line within the box is the median, the lower and upper limits
of the boxes represent the first and third quartiles, and the whiskers 1.53 the interquartile range.
(C) Kaplan-Meier plot of event-free and overall survival of cases (y axis) separated by methylation subclass, time given in months (x axis) and overall p value
calculated by the log rank test.
See also Figure S1 and Table S2.
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Figure 3. Somatic Mutations
(A) Oncoprint representation of an integrated annotation of somatic mutations and DNA copy-number changes for the 30 most frequently altered genes in 86
samples (nR 3, frequency barplot on the right, excluding hypermutator cases). Selected common fusion events are also shown where available. Samples are
arranged in columns with genes labeled along rows.
(B) Barplots are provided on a log10 scale for numbers of copy-number aberrations and somatic mutations per case. Clinicopathological and molecular
annotations are provided as bars according to the included key. CR/PR, complete response or partial response; Stable/NC, stable disease or no change.
See also Figures S2 and S3 and Table S3.H3F3AMutation Confers Poor Prognosis for Both K27M
and G34R/V Substitutions
Histone mutations have been shown to be present in approxi-
mately half of all pHGGs (Mackay et al., 2017), with a clear
negative impact on survival for K27M (Karremann et al., 2018;
Khuong-Quang et al., 2012; Mackay et al., 2017), although the834 Cancer Cell 33, 829–842, May 14, 2018situation is less clear for G34R/V mutations (Bjerke et al.,
2013; Korshunov et al., 2015; Mackay et al., 2017).
H3F3A_G34R/V mutant tumors had a tendency to being
diffusely infiltrative with predominant deep left temporo-parietal
involvement (Figure 4A). There were seven cases with
H3F3A_G34 substitutions (six G34R and one G34V), with six
Figure 4. H3F3A Mutant Subgroups
(A–D) H3F3A_G34R/V. (A) Radiological tumor lesion map of 7 H3F3A_G34R/V cases. Brighter colored pixels indicate a higher probability of tumor incidence.
(B) Integrated annotation of somatic mutations and DNA copy-number changes in H3F3A_G34R/V cases. Clinicopathological and molecular annotations are
provided as bars according to the included key in Figure 3. (C) H&E (top) and immunohistochemistry (bottom) directed against H3.3G34R for HERBY020. Scale
bars, 50 mm. (D) Kaplan-Meier plot of event-free and overall survival of 55 hemispheric cases (y axis) separated by H3F3A status, time given in months (x axis),
p value calculated by the log rank test.
(legend continued on next page)
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out of seven (86%) cases additionally harboring TP53 and/or
ATRX mutations (five out of seven, 71% both), while five out of
seven (71%) also contained PDGFRA amplification and/or
mutation (Figure 4B). There were no other recurrent mutations,
although isolated instances of mutations in PI3K signaling
(PIK3CA and PTEN) and DNA repair (ERCC1) were observed
(Table S3). Histologically, there were four GBM, two AA with
multinucleated cells, and one HGG, not otherwise specified
(Figure 4C). Tumors were Olig2 negative (7/7) with strong
nuclear accumulation of p53 (6/7). Across all tumors within
this hemispheric subgroup, patients harboring these mutations
trended toward a shorter EFS (median = 8.3 months;
p = 0.0572, log rank test) and had a significantly shorter OS
(median = 12.0 months; p = 0.00765, log rank test) (Figure 4D),
although this association was lost when IDH1, PXA-like, and
LGG-like tumors were excluded (p = 0.440 EFS and p = 0.139
OS, log rank test) (Figure S4A).
By contrast, K27M substitutions were restricted to midline re-
gions (n = 24). Two patients had distinct, separate lesions in the
thalamus and hypothalamus, while the remaining had central
thalamic, midbrain, or cerebellar localization (Figure 4E). Fifteen
out of 21 (71%) exome-sequenced cases carried additional am-
plifications/mutations in the receptor-tyrosine kinase (RTK)-PI3K
pathway across a range of genes (PDGFRA, MET, IGF1R,
FGFR1, PTEN, PIK3CA, and PIK3R1), with five out of six of the
remaining tumors harboring ATRX mutation (Figure 4F; Table
S3). There was strong immunoreactivity for H3K27M in 12/12
cases tested (Figure 4G). Although conferring a worse prognosis
across the whole cohort (above), within midline locations
there was no association with either EFS (median = 7.9 months;
p = 0.482, log rank test) or OS (median = 14.2 months; p = 0.839,
log rank test) (Figure 4H), nor any prognostic value for WHO-
grade in K27M tumors (p = 0.646 EFS and p = 0.762 OS, log
rank test) (Figure S4B).
Immune-Positive Subgroups Are Associated with MAPK
and Benefit from the Addition of BEV
pHGGs with a high mutational burden had previously been
described to have an elevated neoantigen load and a pro-
nounced immune response (Bouffet et al., 2016). Four cases
were classed as hypermutator, with a median somatic mutation
count of 4,848 (range = 2,197–5,332; mutation rate 160–240 mu-
tations/Mb) (Figure 5A, Table S1). Mutation signature analysis
showed predominantly C > T transitions and hotspot somatic
POLE mutations in three cases, and a somatic POLD1 mutation
in the fourth (Figure 5B). They were all categorized as GBM, and,
in one case, the presumed mismatch repair deficiency was
demonstrated by clear loss of MLH1 expression by immunohis-
tochemistry (Figure 5C). This specimen had a heterogeneous
immune phenotype, with a relatively high percentage of CD8+
cells in the central area, and in three or four thin perivascular
cuffs (Figure 5D; Table S4). These hypermutator cases had the
highest percentage of CD8+ cells (p < 0.0001 t test versus rest(E–H) H3F3A_K27M. (E) Radiological tumor lesion map of 21 H3F3A_K27M case
Integrated data fromH3F3A_K27M cases. Clinicopathological and molecular ann
(top) and immunohistochemistry (bottom) directed against H3.3K27M for HERBY0
34 midline cases (y axis) separated by H3F3A status, time given in months (x ax
See also Figure S4.
836 Cancer Cell 33, 829–842, May 14, 2018excluding PXA-like) (Figure 5E). Notably, PXA-like tumors were
also significantly enriched for CD8+ cells (p < 0.0001 t test versus
rest excluding hypermutator). Of three HGG-WT cases with
relatively high immune infiltrate, two had elevated somatic SNV
counts (100–110 per case), while the third scored highly for the
GBM_LYMPH_HI subgroup by methylation profiling. A formal
histological assessment of tumor-infiltrating lymphocytes (TILs)
confirmed the highest-scoring categories (lymphocytes scat-
tered among tumor cells/in more than 50% of the tumor) to be
almost exclusively present in hypermutator and PXA-like sub-
groups (Figure S5A; Table S4), as were those cases formally
classified as an inflamed immune phenotype (Figure S5B;
Table S4). Histone mutant tumors were notably immune cold
as defined by a lack of CD8 immunoreactivity and an absence
of TILs.
Nine cases classified by 450k methylation profiling as more
similar to PXAs than HGGs. Five out of nine (55%) harbored
BRAF_V600E mutations, with three out of five (60%) also
containing CDKN2A/B deletions and/or TERT amplification or
promoter mutation (C250T) (Figure 6A). Three of four of the re-
maining cases were instead found with somatic NF1 mutation,
often in concert with TP53 (three out of four) and/or ATRXmuta-
tion (two out of four). Upon histological re-review according to
WHO 2016 guidelines by the HERBY Pathology Committee,
BRAF_V600E, cases were all found to comprise the epithelioid
variant of grade IV GBM, while the NF1 cases were all classified
as the giant cell variant (Figure 6B). PXA-like tumors had a high
degree of immune infiltrate, with cases exhibiting several peri-
vascular cuffs of more than three layers of CD8+ T cells, which
were also scattered among tumor cells in more than 50% of
the specimen (Figure 6C). They were found bilaterally restricted
to temporo-parietal regions with a medial hemispheric predom-
inance (Figure 6D).
Gene expression data from RNA-seq were available for a sub-
set of samples, in which a CD8 T effector/T cell signature was
found to correlate with CD8 positivity by immunohistochemistry
(r2 = 0.49138, p = 0.00523), with two hypermutator cases as out-
liers (Figure 7A). Although no PXA-like or BRAF_V600E mutant
cases were included in this subset, these signatures were partic-
ularly evident in cases with predicted MAPK pathway-activating
alterations in NF1 (truncating frameshift/nonsense, disrupting
translocation or predicted damaging missense), NTRK2 (translo-
cation or tandem duplication of kinase domains), and FGFR1
(known activating hotspot mutation) (Figure 7B). Gene set enrich-
ment analysis (GSEA) showed multiple enrichments for gene sets
associated with T cell signaling and the immune response
(e.g., PID_CD8_TCR_ DOWNSTREAM_PATHWAY, enrichment
score = 0.594, nominal p = 0.0020; KEGG_T_CELL_RECEPTOR_
SIGNALING_PATHWAY, enrichment score = 0.532, nominal
p = 0.0297) and inflammatory-related MAPK signaling
(e.g., ST_JNK_MAPK_PATHWAY, enrichment score = 0.466,
nominal p = 0.0332; REACTOME_GRB2_SOS_PROVIDES_
LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS,s. Brighter colored pixels indicate a higher probability of tumor incidence. (F)
otations are provided as bars according to the included key in Figure 3. (G) H&E
15. Scale bars 50 mm. (H) Kaplan-Meier plot of event-free and overall survival of
is), p value calculated by the log rank test.
Figure 5. Hypermutator Cases
(A) Circos plots for four hypermutator cases. In each case, plots provide somatic SNVs and insertion/deletions on the outer ring, DNA copy-number changes (dark
red, amplification; red, gain; dark blue, deletion; blue, loss), and loss of heterozygosity (yellow) on the inner rings, and intra- (orange) and inter- (blue) chromosomal
translocations inside the circle.
(B) Mutation signatures. Top: simple stacked barplot representation of the proportion of mutation types observed in individual hypermutator cases and the
remaining accumulated dataset. Base changes given in the key. Bottom: mutation context given for each of the 96 mutated trinucleotides, represented by
heatmap. The base located 50 to each mutated base is shown on the vertical axis, and the 30 base is on the horizontal axis.
(C) H&E (top) and protein expression of mismatch repair proteins (bottom panel, clockwise from top left: MLH1, MSH2, MSH6, and PMS2) as assessed by
immunohistochemistry in a glioblastoma with 5,322 somatic mutations (HERBY102). Scale bars, 100 mm (H&E, MLH1, MSH2) or 50 mm (MSH6, PMS2).
(D) CD8 expression in T cells by immunohistochemistry in HERBY102. Scale bar, 100 mm.
(E) Boxplot of percentage of CD8+ cells in the central tumor region separated by subgroup. The thick line within the box is themedian, the lower and upper limits of
the boxes represent the first and third quartiles, and the whiskers 1.53 the interquartile range. ***p < 0.0001, t test.
See also Figure S5 and Table S4.enrichment score = 0.581, nominal p = 0.0239) (Table S5), with
mean T effector/T cell signature significantly higher than in cases
without MAPK alterations (p = 0.0039, t test) (Figure 7C). This was
validated in a restricted cohort of n = 59 patients from our retro-
spective analysis designed to approximate the HERBY cohort
(i.e., non-brainstem pHGGs aged 3–18 years), in which we
observed a significantly elevated T effector/T cell gene expression
signature in MAPK-altered samples (p = 0.0018, t test) (Figures
S6A and S6B), further demonstrated by GSEA (e.g.,
PID_CD8_TCR_DOWNSTREAM_PATHWAY, enrichment score =
0.551, nominal p = 0.0099; BIOCARTA_TCR_PATHWAY enrich-
ment score = 0.520, nominal p = 0.0305) (Table S5).We also explored other immune-related gene expression sig-
natures in the RNA-seq data, and noted a trend toward an
elevated macrophage M2 response in MAPK-altered tumors
(p = 0.0810, t test) (Figures S6C and S6D). We performed
CD68 staining for a limited number of cases with a histologically
defined immune response (n = 11), and found a heterogeneously
distributed tumor-associated macrophages (TAM) component,
comprising either TAM-free tumoral areas, or rich TAM areas
especially around necrotic foci or associated with perivascular
lymphocytes (Figure S6E). BRAF_V600E cases had CD68+
TAM more diffusely intermingled with tumor cells (Figure S6E).
Although the presence of macrophage infiltration has previouslyCancer Cell 33, 829–842, May 14, 2018 837
Figure 6. PXA-like Tumors
(A) Integrated annotation of somatic mutations
and DNA copy-number changes in nine samples
classifying as PXA-like. Clinicopathological and
molecular annotations are provided as bars
according to the included key in Figure 3.
(B) H&E staining of an epithelioid (top, HERBY104)
and giant cell (bottom, HERBY098) variant of
glioblastoma. Scale bars, 100 mm.
(C) CD8 immunohistochemistry for the same cases
as (B), marking CD8+ T cells. Scale bars, 100 mm.
(D) Radiological tumor lesion map of PXA-like
cases. Brighter colored pixels indicate a higher
probability of tumor incidence.been reported in diffuse intrinsic pontine glioma (Caretti et al.,
2014), we observed no association of the M2 gene expression
signature with K27M midline tumors in our cohort (p = 0.965).
With the primary efficacy analysis failing to demonstrate sur-
vival differences between the two arms, we explored whether
the molecular-profiling data could identify subsets of patients
whomay have benefited from the addition of BEV to the standard
chemoradiotherapy. We performed a univariate Cox regression
analysis on methylation-based molecular subgroups, as well
as individual gene-level alterations, and found none which had
significant difference in outcome between investigational arms
(Figure S7A), although NF1, PDGFRA, and TP53 were adverse
prognostic markers across the whole cohort (Figures S7B–
S7E). Notably, however, while not predictive in the TMZ/RT
arm (Figure 7D), the presence of high levels of CD8+ T cells within
the central tumor area conferred a significantly better OS in chil-
dren receiving the addition of BEV (p = 0.0404, log rank test) (Fig-
ure 7E). Fitting a Cox interaction model (with proportional haz-
ards confirmed by calculating Schoenfeld residuals, p = 0.268),
high CD8 levels trended toward predictivity of response to
TMZ/RT+BEV,with a hazard ratio of 0.360 (p = 0.066). In keeping
with the strong subgroup associations described, 17/18 cases
with high levels of CD8+ T cells are hemispheric (representing
38.6% cases in this location). Within hemispheric tumors
only, there is a significant interaction between high CD8 and
BEV (hazard ratio [HR] = 0.251, p = 0.024).
DISCUSSION
The HERBY trial opened in October 2011, prior to the discovery
of histone gene mutations in 2012 (Schwartzentruber et al.,
2012), and the more extensive genome sequencing published
in 2014 (Wu et al., 2014), and there were no molecular markers
incorporated into trial design. The present correlative biology
study demonstrates the extent of the heterogeneous population
of tumors, with widely differing biological drivers and clinico-
pathological features that were included in the cohort. An impor-838 Cancer Cell 33, 829–842, May 14, 2018tant example is the four adolescent pa-
tients with IDH1 mutation, who had a
significantly better clinical outcome, and
may now be thought of as the lower age
limit of an adult subgroup rather than
pHGGs. Such patients will likely be
included in future IDH1-focussed trialsacross adult and pediatric oncology services in order to maxi-
mize the possibility of positive trial outcomes. Similarly, within
the HERBY cohort were seven patients with BRAF_V600E muta-
tions, who would now be candidates for upfront trials of targeted
inhibitors such as vemurafenib (Bautista et al., 2014; Robinson
et al., 2014), and four hypermutator patients, with somatic
POLE/POLD1 mutations and likely harboring biallelic mismatch
repair deficiency syndrome, who may benefit from immune
checkpoint inhibitors such as nivolumab (Bouffet et al., 2016).
In both instances, early clinical data show remarkably promising
results and there would be little justification in their continued in-
clusion in catch-all HGG trials.
Notably, both hypermutator cases, and those biologically
resembling PXAs, the latter of which harbored either BRAF- or
NF1-driven MAP-kinase alterations, were found to be the most
immunogenic in terms of CD8+ T cells/TILs, including a signifi-
cantly elevated CD8 effector T cell gene expression signature.
This is important given reports in adult GBM of an immunosup-
pressive phenotype associated with an elevated CD8+ regulato-
ry T cell immune infiltrate (Kmiecik et al., 2013). The MAPK-
altered hypermutator and PXA-like pediatric cases in the present
cohort were found to benefit from the addition of BEV to TMZ/RT
as regard to overall, although not EFS, the first and only such
predictive biomarker identified in this patient population. The
immunomodulatory effects of anti-angiogenic therapies have
been previously demonstrated in other cancer types (Elamin
et al., 2015), with VEGF-A shown to play an important role in
the induction of an immunosuppressive environment (Gabrilo-
vich et al., 1996), through increasing PD-L1 and other inhibitory
checkpoints involved in CD8+ T cell exhaustion.
An important implication of these observations is the possibil-
ity of overcoming resistance to BRAF/MEK-targeting therapies
by combining them with BEV and/or other immune therapies in
these subgroups, as has been suggested in melanoma (Hu-
Lieskovan et al., 2015). Such a strategy is, however, complicated
by the diverse roles on T cell function played by MAPK signaling.
Although involved in the regulation of T cell proliferation and
Figure 7. Immune Signatures and Response to BEV
(A) Mean T effector/T cell gene expression values (plotted as log2, x axis) were correlated with CD8 immunoreactivity (plotted as log10, y axis) for 18 cases.
Two cases were scored as 0% by immunohistochemistry and were not plotted (expression values 7.37 and 7.58).
(B) Gene expression signatures for CD8 T effector and T cells plotted as a heatmap from 20 cases with RNA-seq data. Hypermutator cases and those with MAPK
alterations including NF1, FGFR1, or NTRK2 are annotated.
(C) Plot of T effector/T cell gene expression values inMAPK-altered samples compared with those without. Horizontal bar represents themean, error bars the SD.
(D) Kaplan-Meier plot of event-free and overall survival of 36 cases (y axis) treated with TMZ/RT, separated by levels of CD8+ T cells, time given in months (x axis),
and p value calculated by the log rank test.
(E) Kaplan-Meier plot of event-free and overall survival of 34 cases (y axis) treatedwith TMZ/RT plus BEV, separated by levels of CD8+ T cells, time given inmonths
(x axis), and p value calculated by the log rank test.
See also Figures S6 and S7 and Table S5.survival (D’Souza et al., 2008), selective BRAF inhibitors have
been shown to increase CD8+ lymphocytes in human metastatic
melanomamodels (Wilmott et al., 2012). Crucially, althoughMEK
inhibition has been demonstrated to block naive CD8+ T cell
priming in a colon cancer model, the number of CD8+ effector
T cells within the tumor were increased, and could potentiate
immune checkpoint therapy (Ebert et al., 2016). A limitation of
the present study is the small numbers in this post-hoc analysis,
and the benefit that patients with these biological subgroups
may derive from an immunomodulatory mechanism of BEV
would need to be tested in the prospective setting. This is a
challenge given that these patients represent approximately
10%–15% of an already rare disease; however, international
collaborative trials groups (such as those in HERBY represent),
already recruit hypermutator and MAPK-altered HGGs in this
population for appropriately targeted therapies (NCT02992964,
NCT02684058). Equally importantly, the histone H3 mutant sub-
groups, which represent a substantial proportion of patients in
this age group (Mackay et al., 2017) were found to be very poorly
immunogenic, confirming a previous study in resectable malig-nant brainstem gliomas in children and adults with K27M muta-
tions (Zhang et al., 2017), and further negating the likelihood of
clinical response to such therapies.
A key observation is the high prevalence of tumors occurring
outside the cerebral hemispheres harboring histone mutations,
included in the most recent 2016 WHO classification system as
a separate entity called diffuse midline glioma with H3K27M mu-
tation. These represented 27% of the assessed population, and
had a particularly poor outcome, as did histoneWTmidline cases.
These tumors only rarely haveMGMT promoter methylation, and
have consistently proved refractory to TMZ and other chemother-
apeutic agents (Jones et al., 2016). Critically, midline K27M tu-
mors classified histologically as either grade 3 or 4 according to
theWHO 2007 classification had no difference in clinical outcome
within the HERBY cohort, and with the caveat of small numbers,
support the current 2016 guidelines to assign all such tumors as
grade 4 on the basis of their location and molecular findings.
More surprising was the poor outcome observed for patients
with H3F3A_G34R/V mutations. A previous study reported
G34R mutations to convey a better prognosis in respect of OSCancer Cell 33, 829–842, May 14, 2018 839
(HR = 0.49, p = 0.01), although this was not significant in multi-
variate analysis (p = 0.84) (Korshunov et al., 2015), although
the present study explores this in a consistently treated and
well-annotated clinical trial setting. In the HERBY study, as well
as in published work (Korshunov et al., 2015; Mackay et al.,
2017), the H3F3A_G34R/V mutation is associated with a high
frequency of MGMT methylation. Notably, MGMT promoter
methylation itself was not predictive in this trial cohort of all pa-
tients receiving radiochemotherapy with TMZ, again demon-
strating differences with the adult disease, and questioning the
continued use of protocols extrapolated from the adult setting.
It is clear that histonemutations represent clearly defined entities
within an umbrella HGG classification in the pediatric setting,
and given their profound impact on chromatin modifications,
will require therapeutic development and clinical trials distinct
from histone WT cases.
Within the remaining cases of pHGG were a small proportion
whose methylation profiles were more similar to other lesions.
The LGG-like cases were in young patients with longer EFS,
while two additional cases had methylation classifier scores
strongly suggestive of recently described entities coming from
the study of tumors formally diagnosed as CNS primitive
neuroectodermal tumors (Sturm et al., 2016). Integration with
histological features and determination of the presence of
marker gene fusions events for these entities (CNS HGNET-
MN1, CNS NB-FOXR2) will be key in future studies.
Although there have been several early-phase and anecdotal
studies of BEV in pHGG (Benesch et al., 2008; Friedman et al.,
2013; Gururangan et al., 2010; Narayana et al., 2010; Salloum
et al., 2015), none have included biological information on the
patients treated. Aside from CD8 immunoreactivity, we did not
identify any additional molecular markers of response. In simi-
larly designed adult studies of BEV, gene expression-defined
proneural (Sandmann et al., 2015) or mesenchymal (Sulman
et al., 2013) subgroups of GBM have been reported to confer a
significant OS advantage. Although we have not undertaken
gene expression studies across our cohort, adult and pediatric
cases expressing proneural genes appear to have distinct ge-
netic and epigenetic drivers (Sturm et al., 2012), the mesen-
chymal subclass is rare in children (Sturm et al., 2012), and unlike
the adult studies, we observed no EFS advantage of BEV in
HERBY (Grill et al., 2018).
In conclusion, integrated molecular profiling of the HERBY
sample cohort has demonstrated the biological and clinicopath-
ological diversity of the term HGG in the pediatric setting, sus-
pected but not confirmed at the onset of the trial. While there
are several distinct subgroups for which there is strong rationale
for bespoke future clinical studies, a large proportion of pHGG
cases continue to defy improvements in survival and lack a clear
path forward. Although BEV was not associated with better
outcome in this trial, the extensive biological, pathological, and
radiological ancillary research programs ongoing within HERBY
aim to provide an integrated assessment of disease pathogen-
esis and treatment response.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient Samples
All patient samples were collected after signed consent to the HERBY translational research program, under full Research Ethics
Committee approval at each participating center. Tumor material was available from 89 patients (out of a total of 113 providing
consent) from 13 countries: France (n=27, Hospital Pour Enfants De La Timone, Marseille; Hoˆpital des Enfants, Toulouse; Centre
Hospitalier Re´gional Universitaire, Tours; CHRU Rennes; CHRU Nancy; Institut Curie, Paris; CHRU Strasbourg; Cancer Research
Center of Lyon; Institut Gustave Roussy, Villejuif; CHRU Clermont-Ferrand; Oscar Lambret Center, Lille; CHRU Angers), UK
(n=17, Royal Victoria Infirmary, Newcastle; NHS Lothian, Edinburgh; Nottingham University Hospital, Nottingham; Great Ormond
Street Hospital, London; Royal Hospital for Children, Bristol; Cambridge University Hospital, Cambridge; Leeds Teaching Hospitals,
Leeds; Alder Hey Children’s Hospital, Liverpool; Royal Marsden Hospital, Sutton), Italy (n=14, Istituto Giannina Gaslini, Genoa;
Istituto Nazionale Tumori, Milan), Spain (n=6, Hospital San Joan de Deu, Barcelona; Hospital Universitari i Polite`cnic la Fe, Valencia),
Canada (n=5, Hospital for Sick Children, Toronto; Alberta Children’s Hospital, Calgary), Netherlands (n=4, Radboud University
Medical Center, Nijmegen; Erasmus Medical Center, Rotterdam), Czech Republic (n=3, Faculty Hospital, Brno; Charles University
Hospital, Prague), Denmark (n=3, Aarhus University Hospital, Aarhus; Rigshospitalet, Copenhagen), Hungary (n=3, Semmelweis
University, Budapest), Sweden (n=3, University of Gothenburg, Gothenburg; Ska˚ne University Hospital, Lund), Poland (n=2,
Children’s Memorial Health Institute, Warsaw), Austria (n=1, Kepler Universit€atsklinikum, Linz), and Belgium (n=1, Universitaire
Ziekenhuizen, Leuven).
Pathological Review
All patients had their initial local diagnosis of HGG confirmed according to theWHO 2007 classification by a central HERBY reference
neuropathologist prior to enrollment. Subsequently, all specimens were further subjected to a consensus review by the HERBY panel
of five independent expert paediatric neuropathologists, who also applied the diagnostic criteria of the WHO 2016 classification.
Radiological Anatomical Localization
Tumor localization was determined by the HERBY panel of paediatric neuroradiologists. Tumors were assigned to lobar, basal
ganglia, thalamic, non-pontine brainstem or cerebellar locations. As many of the tumors spanned more than one of these locations,
post hoc radiological analysis by one of the HERBYNeuroradiologists was undertaken to determine the epicenter of the tumor origin;
this was used to classify the site of origin of the tumor in each case.e2 Cancer Cell 33, 829–842.e1–e5, May 14, 2018
METHOD DETAILS
Nucleic Acid Extraction
DNAwas extracted from frozen tissue by homogenisation prior to following the DNeasy Blood & Tissue kit protocol (Qiagen, Crawley,
UK). DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) pathology blocks after manual macrodissection using the
QIAamp DNA FFPE tissue kit protocol (Qiagen). Matched normal DNA was extracted from blood samples using the DNeasy Blood
& Tissue kit (Qiagen, Crawley, UK). Concentrations were measured using a Qubit fluorometer (Life Technologies, Paisley, UK). RNA
was extracted by following the RNeasy Mini Kit protocol (Qiagen), and quantified on a 2100 Bioanalyzer (Agilent Technologies).
H3F3A Sanger Sequencing
PCR for H3F3A was carried out on 89 cases using primers obtained from Life Technologies (Paisley, UK) (FFPE: for-TGGCTCGTA
CAAAGCAGACT; rev-ATATGGATACATACAAGAGAGACT; FROZEN: for-GATTTTGGGTAGACGTAATCTTCA; rev-TTTCCTGTTA
TCCATCTTTTTGTT). Sequences were analysed using Mutation Surveyor (SoftGenetics, PN, USA) and manually with 4Peaks
(Nucleobytes, Aalsmeer, Netherlands). Only three cases left insufficient DNA for exome sequencing, all of which were found to harbor
K27M mutations, and thus additional Sanger sequencing for genes encoding H3.1 variants were not undertaken.
Methylation Profiling
50-500 ngDNAwasbisulphite-modified and analyzed for genome-widemethylation patterns using the IlluminaHumanMethylation450
BeadChip (450k) platform at either the DKFZor theUniversity College LondonGenomicsCenter, according themanufacturers instruc-
tions. All samples were checked for expected and unexpected genotypematches by pairwise correlation of the 65 genotyping probes
on the 450k array.
MGMT Promoter Methylation
To evaluate the methylation status of theMGMT promoter region, we used either the MGMT_STP27 logistic regression model from
Illumina 450k methylation array data, or methylation-specific (MS-) PCR. For MS-PCR, 300-1500 ng DNA was sodium bisulphite-
treated and PCR products analyzed on an the ABI7900HT instrument (Applied Biosystems, Foster City, CA, USA) to quantify the
copy number of MGMT/ACTB (MDxHealth, Irvine, CA, USA).
Next-Generation Sequencing
50-500 ng DNA from 86 cases was sent for exome sequencing at the Tumor Profiling Unit (ICR, London, UK) using the Agilent
SureSelectXT Human All Exon V6 platform with additional customized coverage of all histone H3 genes and the TERT promoter
(Agilent, Santa Clara, CA, USA), and paired-end-sequenced on an Illumina HiSeq2500 (Illumina, San Diego, CA, USA) with one single
patient-matched tumor/normal pair per lane where possible. The average median coverage was 426x for the frozen tumors (range
351-598x), 321x for the FFPE tumors (range 115-519x) and 163x for normal samples (range 116-464x). A customized panel of
biotinylated DNA probes (NimbleGen) was developed for the detection of structural variants (translocations and duplications) and
potential amplifications. The panel capture a total of 22 genes recently implicated in brain tumors (ALK, BCOR, BRAF, c11orf95,
C19MC, CIC, ETV6, FGFR1-3, FOXR2, KIAA1549, MET, MN1, MYB, MYBL1, NTRK1-3, RAF, RELA, TPM3 and YAP1). Library
preparation was performed using 50-200 ng of genomic DNA using the HyperPlus Kit (Kapa Biosystems, Wilmington MA, USA)
and SeqCap EZ adapters (Roche). Following fragmentation, DNA was end-repaired, A-tailed and indexed adapters ligated. DNA
was amplified, multiplexed and hybridized using 1 mg of total pre-capture library DNA to the design of DNA baits (NimbleGen SeqCap
EZ Developer library, Roche). After hybridization, capture libraries were amplified and sequencing was performed on a NextSeq500
(Illumina) with 2 x 150 bp, paired-end reads following manufacturer’s instructions. RNA from frozen tumors was sequenced on an
Illumina HiSeq2500 as 100 bp paired end reads.
Immunohistochemistry
4 mMsections were stained by an automated Discovery XT (for H3G34R) or Benchmark XT (VentanaMedical Systems, Tucson, USA).
A standard pre-treatment protocol included CC1 buffer (or CC2 for H3G34R) and then a primary antibody incubation for 32 minutes
(92 minutes for MLH1, PMS2, MSH2 and MSH6) at room temperature (37C for H3K27M and MLH1). Antibodies used were directed
against MLH1 (BD Pharmingen, clone G168-728, 1/300), PMS2 (BD Pharmingen, clone A16-4, 1/150), MSH2 (DIAG-BIOSYSTEMS,
clone 25D12, 1/10), MSH6 (DIAG-BIOSYSTEMS, clone 44, 1/50), H3K27M (Merck, polyclonal, 1/1000), CD8 (Dako, clone C8/144B,
1/100), CD68 (Glostrup, clone KP1, 1/400) and H3G34R (kind gift from Richard Grundy, Children’s Brain Tumor Research Center,
Nottingham, UK, polyclonal; 1/150). Antibody binding was visualized with an Optiview Kit (Roche-Ventana, Tucson, USA). Diamino-
benzidine-tetra-hydrochloride (DAB, Ventana) was used as the chromogen.
Pathological Assessment of Immune Response
CD8 immunoreactivity was assessed as the percentage of the surface area of the tumor covered by CD8+ cells present at a density
belonging to one of four reference bins of increasing density (I0, I1, I2, I3). A further quantitative assessment of the percentage of the
pathologist-defined central tumor area of CD8+ cells was also performed. A qualitative categorization of the tumor as a whole as
either ‘inflamed’, ‘heterogeneous’ or an immune ‘desert’ was also provided. Patients in the upper quartile of central tumor areaCancer Cell 33, 829–842.e1–e5, May 14, 2018 e3
CD8 cell positivity with a heterogeneous or inflamed phenotype were classed as CD8-high. A histologically-defined assessment of
tumor infiltrating lymphocytes (TILs) was carried out according to two distinct schema. Palma et al. (Palma et al., 1978) includes
Category A (several perivascular cuffs of more than three layers of lymphocytes and often lymphocytes also scattered among tumor
cells), Category B (three or four thin perivascular cuffs in the tumor) and Category C (no clear lymphocytes present); Rutledge et al.
(Rutledge et al., 2013) includes Category 0 (absence of lymphocytes), Category 1+ (lymphocytes in less than 50% of the tumor) and
Category 2+ (lymphocytes in more than 50% of the tumor).
QUANTIFICATION AND STATISTICAL ANALYSIS
Sequence Analysis
Exome capture reads were aligned to the hg19 build of the human genome using bwa v0.7.5a (bio-bwa.sourceforge.net), and PCR
duplicates removed with PicardTools 1.5 (pcard.sourceforge.net). Somatic single nucleotide variants were called using the Genome
Analysis Tool Kit v3.3-0 based upon current Best Practices using local re-alignment around InDels, downsampling and base recali-
bration with variants called by the Unified Genotyper (broadinstitute.org/gatk/). Somatic variants were covered by at least 20 reads in
both tumor and normal sequences and carried at least 5 ALT reads in the tumor sequence; unmatched exomes (n=3) were annotated
by ExAc and ANNOVAR. Variants were annotated using the Ensembl Variant Effect Predictor v74 (ensembl.org/info/docs/variation/
vep) incorporating SIFT (sift.jcvi.org) and PolyPhen (genetics.bwh.harvard.edu/pph2) predictions, COSMIC v64 (sanger.ac.uk/
genetics/CGP/cosmic/) and dbSNP build 137 (ncbi.nlm.nih.gov/sites/SNP) annotations. Copy number was obtained by calculating
log2 ratios of tumor/normal coverage binned into exons of known Ensembl genes, smoothed using circular binary segmentation
(DNAcopy, www.bioconductor.org) and processed using in-house scripts. Mutation signatures were ascertained by grouping so-
matic substitutions on the basis of their 30 and 50 bases into 96 possible trinucleotide categories (Shlien et al., 2015). NGS fusion panel
alignment was performed against the human reference sequence GRCh37/Hg19. Quality control (QC), variant annotation, dedupli-
cation and metrics were generated for each sample. Manta (https://github.com/Illumina/manta) and Breakdancer (breakdancer.
sourceforge.net) were used for the detection of structural variants.
Methylation Profiling
Methylation data from the Illumina Infinium HumanMethylation450 BeadChip was preprocessed using the minfi package in R. DNA
copy number was recovered from combined intensities using the conumee package with reference to methylation profiles from
normal individuals provided in the CopyNumber450kData package. We have used the Heidelberg brain tumor classifier (Capper
et al., 2018) (molecularneuropathology.org) to assign subgroup scores for each tumor compared to 91 different brain tumor entities
using a training set built from 2,801 tumors implemented in the MNP R package (v11b2). Simplified methylation subgroup assign-
ments were then made to incorporate cases carrying G34R/V or K27M mutations in H3 histones, IDH1mutation at R132, low grade
glioma-like profiles (predominantly diffuse infantile ganglioglioma and pilocytic astrocytoma) and those similar to pleomorphic
xanthoastrocytoma (PXA). Low-scoring cases, or those with a high normal cell contamination were assigned to G34, K27 or IDH1
groups if the respective mutation was identified. Wild-type HGG encompassed many other methylation subgroups and were simply
assigned by exclusion with the groups above. Clustering of beta values from methylation arrays was performed using the 10K
probeset from the Heidelberg classifier based upon Euclidean distance with a ward algorithm. Methylation heatmaps show only
the most variable probes of the classifier between simplified methylation subgroups.
RNAseq
RNA sequences were aligned to hg19 and organized into de-novo spliced alignments using bowtie2 and TopHat version 2.1.0
(ccb.jhu.edu/software/tophat). Fusion transcripts were detected using chimerascan version 0.4.5a filtered to remove common
false positives. RNASeq raw count files were used to construct an expression matrix using Roche’s internal pipeline. The expres-
sion matrix was normalized using edgeR and Voom in R (cran.rproject.org/), and a heatmap was created from the absolute gene
expression data using Tibco Spotfire, as previously described (Brouwer-Visser et al., 2018). The mean expression of the signature
genes was used to compare MAPK-altered to non-altered samples and statistical significance calculated using a two-tailed
unpaired t-test. The mean expression was also used to correlate with CD8 positivity by IHC. Gene Set enrichment analysis was
performed using the GSEA java application based upon pairwise comparisons of MAPK altered versus wild-type for curated
canonical gene sets. All data are deposited in the European Genome-phenome Archive (ebi.ac.uk/ega/home) under accession
number EGAS00001002328.
Tumor Lesion Maps
Pre-surgery tumor volume regions of interest (ROIs) were drawn on T2-weighted/Fluid-attenuated inversion recovery (FLAIR)
magnetic resonance (MR) images by an experienced paediatric neuroradiologist (TJ). The images and corresponding ROIs were
affinely registered, using FSL (Jenkinson et al., 2002), to a paediatric template (Left-Right Symmetric, 7.5–13.5 years old) from the
Montreal Neurological Institute (http://www.bic.mni.mcgill.ca/ServicesAtlases/NIHPD-obj1) (Fonov et al., 2011). A further manual
correction step was performed to limit tumor mass effects. Once registered to a common space, overall tumor lesion overlap
maps were created using MRIcron (Rorden et al., 2007).e4 Cancer Cell 33, 829–842.e1–e5, May 14, 2018
Statistical Analysis
Statistical analysis was carried out using R 3.3.0 (www.r-project.org) and GraphPad Prism 7. Categorical comparisons of counts
were carried out using Fishers exact test, comparisons between groups of continuous variables employed Student’s t-test or
ANOVA. Univariate differences in survival were analysed by the Kaplan-Meier method and significance determined by the log-
rank test. Exploratory Cox regression analyses were conducted to assess the impact of molecular prognostic and predictive factors.
Confirmation of proportional hazards was assessed by calculating Schoenfeld residuals. All tests were two-sided and a p value of
less than 0.05 was considered significant.
DATA AND SOFTWARE AVAILABILITY
All newly generated data have been deposited in the European Genome-phenome Archive (www.ebi.ac.uk/ega) with accession
number EGAS00001002328 (sequencing) or ArrayExpress (www.ebi.ac.uk/arrayexpress/) with accession number E-MTAB-5552
(450k methylation).
ADDITIONAL RESOURCES
Curated gene-level copy number, mutation data and RNAseq data are provided as part of the paediatric-specific implementation of
the cBioPortal genomic data visualization portal (pedcbioportal.org). Raw data files are also made available through the Cavatica
NIH-integrated cloud platform (cavatica.org).Cancer Cell 33, 829–842.e1–e5, May 14, 2018 e5
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Figure S1 (related to Figure 2) – MGMT promoter methylation. (A) Barplots of number of 
cases with methylated MGMT promoter, subdivided by methylation subgroup. (B) Kaplan-
Meier plot of event-free and overall survival of cases (y axis) separated by MGMT status, time 
given in months (x axis) and p value calculated by the log-rank test.  
 
 
 Figure S2 (related to Figure 3) – DNA copy number profiling and non-HGG-like entities. (A) 
Heatmap representation of segmented DNA copy number for 86 samples derived from exome 
coverage data (dark red, amplification; red, gain; dark blue, deletion; blue, loss). Samples are 
arranged in columns clustered by gene-level data across the whole genome. 
Clinicopathological and molecular annotations are provided as bars according to the included 
key. CR/PR = complete response or partial response; Stable/NC = stable disease or no 
change. (B-D) CNS HGNET-MN1. Haematoxylin and eosin staining (B) of the case most 
closely resembling CNS HGNET-MN1 (HERBY052), as demonstrated by a boxplot of 
reference methylation classifier scores (C), and the presence of an MN1:CARD6 gene fusion 
by capture panel sequencing (D). Scale bar = 100 µm. (E) Integrated annotation of somatic 
mutations and DNA copy number changes in 3 samples classifying as LGG-like. 
Clinicopathological and molecular annotations are provided as bars according to the included 
key in Figure S1. (F) Haematoxylin and eosin staining of the three cases, all histologically 
classified as glioblastoma – (left) the presence of both low- (upper panel) and high grade 
(lower panel) areas of the tumor harboring BRAF_V600E mutation (HERBY049); (top right) 
case harboring an intragenic FGFR1 duplication (HERBY030; both previous cases classifying 
as pilocytic astrocytoma); (bottom left) a cased from the infant cohort, with a methylation profile 
most closely resembling desmoplastic infantile ganglioglioma (HERBY105). Scale bar = 50 
µm. (G) Radiological tumor lesion map of LGG-like cases. Brighter colored pixels indicate a 
higher probability of tumor incidence.  
 
 
Figure S3 (related to Figure 3) – IDH1 mutant and H3F3A/IDH1/BRAF wild-type tumors.  (A) 
Integrated annotation of somatic mutations and DNA copy number changes in 4 samples with 
IDH1_R132 mutation. Clinicopathological and molecular annotations are provided as bars 
according to the included key in Figure S1. (B) Haematoxylin and eosin staining of cases 
showing astrocytic (top, HERBY005) and oligodendroglial (bottom, HERBY072) histological 
features. Scale bar = 50 µm (top) and 100 µm (bottom). (C) Kaplan-Meier plot of event-free 
and overall survival of cases (y axis) separated by IDH1_R132 status, time given in months 
(x axis) and p value calculated by the log-rank test. (D) Radiological tumor lesion map of IDH1 
cases. Brighter colored pixels indicate a higher probability of tumor incidence. (E) Oncoprint 
representation of an integrated annotation of somatic mutations and DNA copy number 
changes for the 30 most frequently altered genes in 86 samples (n³3, frequency barplot on 
the right, excluding hypermutator cases), ordered by histone and methylation subgroups. 
Selected common fusion events are also shown where available. Samples are arranged in 
columns with genes labelled along rows. Barplots are provided on a log10 scale for numbers 
of copy number aberrations and somatic mutations per case. Clinicopathological and 
molecular annotations are provided as bars according to the included key. CR/PR = complete 
response or partial response; Stable/NC = stable disease or no change. The annotated box 
highlights H3F3A/IDH1/BRAF wild-type ‘HGG-WT’ tumors not otherwise assigned to a 
subgroup. (F) Radiological tumor lesion map of HGG-WT cases. Brighter colored pixels 
indicate a higher probability of tumor incidence. 
 
 
  
 
Figure S4 (related to Figure 4) – H3F3A mutant subgroups.  (A) Kaplan-Meier plot of event-
free and overall survival (y axis) of 31 cerebral hemispheric cases, excluding those classified 
by methylation profiling as IDH1, PXA-like or LGG-like, separated by H3F3A status. Time is 
given in months (x axis) and p value calculated by the log-rank test. (B) Kaplan-Meier plot of 
event-free and overall survival (y axis) of 24 midline H3F3A_K27M cases, separated by WHO 
grade. Time is given in months (x axis) and p value calculated by the log-rank test. 
 
 
  
 
Figure S5 (related to Figure 5) – Immune profiling. (A) Barplot showing relative proportions of 
tumor-infiltrating lymphocytes categorized according to two schema (Palma and Rutledge), of 
72 cases split by pHGG subgroups. (B) Barplot showing relative proportions of histologically 
defined immune phenotype of 72 cases, split by pHGG subgroups. 
 
  
 
Figure S6 (related to Figure 7) – CD8 and CD68 signatures. (A) Gene expression signatures 
for CD8 T effector and T cells plotted as a heatmap from combined gene expression data of 
non-brainstem high-grade glioma in n=59 patients aged 3-18 years from Mackay et al., 2017. 
Hypermutator cases and those with MAPK alterations are annotated.  (B) Boxplot of T effector 
/ T cell gene expression values in MAPK altered samples compared to those without. 
Horizontal bar represents the mean, error bars the standard deviation. (C) Gene expression 
signatures for M2 macrophages plotted as a heatmap from 20 cases with RNAseq data. 
Hypermutator cases and those with MAPK alterations are annotated. (D) Boxplot of M2 
macrophage cell gene expression values in MAPK altered samples compared to those 
without. Horizontal bar represents the mean, error bars the standard deviation. (E) 
Immunohistochemistry directed against CD68, showing positive cells in perivascular areas 
associated with lymphocytes (top, HERBY104, hypermutator) and more diffusely mixed with 
tumor cells (bottom, HERBY102, BRAF_V600E). Scale bar = 50 µm. 
 

Figure S7 (related to Figure 7) – Exploratory biomarker analysis. (A) Hazard ratio plot for a 
univariate Cox regression analysis on a variety of molecular subgroups and alterations in 
respect of event-free survival. Log2 hazard ratios less than zero indicate a better response to 
TMZ/RT plus BEV, ratios greater than zero a better response to TMZ/RT alone. Median (box) 
and 95% confidence intervals (whiskers) are plotted, with size of box proportion to sample 
size on an indicated category of tumors. (B-E) Kaplan-Meier plot of event-free and overall 
survival of cases (y axis) separated by BRAF_V600E (B), NF1 (C), PDGFRA (D) and TP53 
(E) status, time given in months (x axis) and p value calculated by the log-rank test.  
